Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Mercedes Santoro

Showing results (51-60 of 134) with videos related to

Pageof 14
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2010
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimensValentina Svicher, Claudia Alteri, Anna Artese, et al.
PLOS Global Public Health|March 24, 2023
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysisEzechiel Ngoufack Jagni Semengue, Maria Mercedes Santoro, Valantine Ngum Ndze, et al.
AIDS Research and Human Retroviruses|June 22, 2023
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control StudyFrancesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, et al.
International Journal of Antimicrobial Agents|January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohortRoberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
The New Microbiologica|July 18, 2006
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapyMaria Mercedes Santoro, Valentina Svicher, Caterina Gori, et al.
Journal of Global Antimicrobial Resistance|April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitorsDaniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Journal of Clinical Microbiology|July 3, 2015
Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level ViremiaLavinia Fabeni, Giulia Berno, Valentina Svicher, et al.
The Journal of Infectious Diseases|April 19, 2008
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failureValentina Svicher, Stefano Aquaro, Roberta D'Arrigo, et al.
BMC Infectious Diseases|March 16, 2019
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in CameroonDesire Takou, Joseph Fokam, Georges Teto, et al.
Scientific Reports|January 27, 2022
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patientsGeorges Teto, Alex Durand Nka, Joseph Fokam, et al.
Pageof 14

Showing results (51-60 of 134) with videos related to

Sort By:
Pageof 14
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2010
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimensValentina Svicher, Claudia Alteri, Anna Artese, et al.
PLOS Global Public Health|March 24, 2023
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysisEzechiel Ngoufack Jagni Semengue, Maria Mercedes Santoro, Valantine Ngum Ndze, et al.
AIDS Research and Human Retroviruses|June 22, 2023
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control StudyFrancesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, et al.
International Journal of Antimicrobial Agents|January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohortRoberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
The New Microbiologica|July 18, 2006
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapyMaria Mercedes Santoro, Valentina Svicher, Caterina Gori, et al.
Journal of Global Antimicrobial Resistance|April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitorsDaniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Journal of Clinical Microbiology|July 3, 2015
Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level ViremiaLavinia Fabeni, Giulia Berno, Valentina Svicher, et al.
The Journal of Infectious Diseases|April 19, 2008
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failureValentina Svicher, Stefano Aquaro, Roberta D'Arrigo, et al.
BMC Infectious Diseases|March 16, 2019
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in CameroonDesire Takou, Joseph Fokam, Georges Teto, et al.
Scientific Reports|January 27, 2022
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patientsGeorges Teto, Alex Durand Nka, Joseph Fokam, et al.
Pageof 14